Neuro-Immunotherapy: Novel, Adoptive T-cell Immunotherapy

Levite Mia, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research



LifeSciences and BioTechnology   


Immunotherapy, Neuro-Immunotherapy, T cells, Cancer, HNC, HCC, Infectious diseases

Current development stage

TRL3 - Hypothesis testing and initial POC is demonstrated in limited number of in-vitro models

Innovation & Application

The researchers developed a novel type of adoptive T-cell immunotherapy, entitled Neuro-Immunotherapy. The new patient-tailored method constitutes both diagnostic and treatment protocols.

The adoptive/cellular Neuro-Immunotherapy is based on safe, rapid and potent ex-vivo treatment of patient’s own peripheral T cells, by selected natural Neurotransmitters, Neuropeptides or their combinations, all at low physiological concentrations. Then, the 'rejuvenated' T cells (without the Neurotransmitters) are administered back to the patients weekly, for several months. The therapeutic 'package' can be administered once, or repeated for as long as needed, even during many years. 

The adoptive/cellular Neuro-Immunotherapy can improve profoundly multiple beneficial functions and abilities of patient's own T cells to: survive, secrete cytokines, adhere to glycoproteins, migrate and home in vivo towards chemokines and cancer, penetrate disease-affecting organs, resist immunosuppression imposed on T cells by cancer cells, proliferate in response to cancer, and finally eradicate cancer and infectious organisms and lead to cure.

The adoptive Neuro-Immunotherapy can be beneficial for various human pathologies:

  • Cancer of various types
  • Severe infectious diseases
  • Immunodeficiency diseases
  • Neurological diseases, in which patient's own 'rejuvenated' T cells can be curative 
  • Severe injuries/wounds
  • Old age in which improving low immune competence and deficient neuro-immune dialogues is required

The adoptive Neuro-Immunotherapy is very safe since it is based on patient's own T cells, treated only ex-vivo and only with natural Neurotransmitters/Neuropeptides, and only for a few days. No other drugs or treatments are needed ex-vivo or in-vivo. And all the T-cell effects induced by Neurotransmitters/Neuropeptides are mediated via their own natural Neurotransmitters/Neuropeptides receptors, without involving the T cell receptor (TCR), thus minimizing the risk of autoimmunity and of T cell death via Activation-Induced Cell Death (AICD).

The adoptive Neuro-Immunotherapy can stand alone to treat diseases by patient's own T cells 'rejuvenated' ex vivo by Neurotransmitters/Neuropeptides.' In addition, the Neuro-Immunotherapy protocol can be used as 'add on technology', to improve s survival and in vivo functions of any therapeutic T cells injected in vivo, such as CAR-T cells and various others.


The adoptive Neuro-Immunotherapy is reduced into practice in two stages, both being patient-tailored.

Diagnostic stage

The diagnostic stage enables rapid triple selection: of the patients in need for the Neuro-Immunotherapy, of the responsive patients likely to benefit from the Neuro-Immunotherapy, and of the most effective Neurotransmitters, Neuropeptides and their selected combinations, for optimal activation and rejuvenation of the patient's T cells.  At the completion of the diagnostic phase the responsive candidate patients are selected and can proceed to the therapeutic stage, and for each patient a tailored therapeutic protocol is designed.

Therapeutic stage

In the therapeutic stage of the adoptive Neuro-Immunotherapy, a personal T cell bank is created, containing aliquots of patient's T cells 'rejuvenated' by Neurotransmitters/Neuropeptides, and then frozen in liquid nitrogen. Subsequently, aliquots of Neuro-Immunotherapeutic T cells are thawed and administered weekly to the patient, for few months. The therapeutic package can be repeated when needed. The 'rejuvenated' T cells in the T cell bank can serve later also for other therapeutics purposes


The adoptive Neuro-Immunotherapy seems to be safer, easier, quicker and more patient-friendly than any other currently used adoptive immunotherapy of cancer. It also has a potentially boarder use, since it can be applicable for cancer and also other diseases in which 'rejuvenated'  T cells can be therapeutic, since the T cells are 'generically improved' and NOT specific for a given antigen.

The adoptive Neuro-Immunotherapy, if successful, may save lives, and may make subsequent harmful and expensive treatments unnecessary.






Contact for more information:

Shani Bullock
VP, Business Development, Healthcare
Contact ME: